Literature DB >> 9569179

Ins405AsnPro mutation in the von Willebrand factor propeptide in recessive type 2A (IIC) von Willebrand's disease.

L Holmberg1, D Karpman, C Isaksson, A C Kristoffersson, S Lethagen, R Schneppenheim.   

Abstract

The molecular defects of the von Willebrand factor (vWF) have been studied in the patient in whom the von Willebrand disease phenotype IIC was originally described. A six nucleotide insert, AATCCC, was found in exon 11 of the vWF gene, predicting the insertion of the amino acids asparagine and proline between phenylalanine 404 and threonine 405 of the vWF propeptide. The mutation was present in one allele. Analysis of amplification products derived from platelet vWF mRNA showed the other allele to be silent. The patient is thus a compound heterozygote for a null allele and the IIC allele, in accord with the recessive mode of inheritance of the IIC phenotype. Family studies indicated the IIC mutation to have occurred de novo, possibly as a result of a duplication event. In vitro mutagenesis and expression in COS-7 cells confirmed the detrimental effect of the mutation on vWF multimer assembly. Taken together with those of earlier studies the present findings suggest that the IIC phenotype may well be exclusively caused by mutations which result in changes of the amino acid sequence in certain regions of the vWF propeptide. Although in the recently revised classification of von Willebrand's disease variants, the IIC type is included in the 2A category, obviously it constitutes a very distinct subtype.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9569179

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF.

Authors:  Sandra L Haberichter; Ulrich Budde; Tobias Obser; Sonja Schneppenheim; Cornelia Wermes; Reinhard Schneppenheim
Journal:  Blood       Date:  2010-03-24       Impact factor: 22.113

Review 2.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

3.  Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.

Authors:  Almudena Pérez-Rodríguez; Aranzazu García-Rivero; Esther Lourés; Maria Fernanda López-Fernández; Angela Rodríguez-Trillo; Javier Batlle
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

4.  Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.

Authors:  T Obser; M Ledford-Kraemer; F Oyen; M A Brehm; C V Denis; R Marschalek; R R Montgomery; J E Sadler; S Schneppenheim; U Budde; R Schneppenheim
Journal:  J Thromb Haemost       Date:  2016-08-20       Impact factor: 5.824

5.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

6.  Genetic alteration of the D2 domain abolishes von Willebrand factor multimerization and trafficking into storage.

Authors:  S L Haberichter; A M Allmann; M A Jozwiak; R R Montgomery; J C Gill
Journal:  J Thromb Haemost       Date:  2009-01-17       Impact factor: 5.824

7.  Identification and functional analysis of a novel von Willebrand factor mutation in a family with type 2A von Willebrand disease.

Authors:  Jing Dong; Xiaojuan Zhao; Sensen Shi; Zhenni Ma; Meng Liu; Qingyu Wu; Changgeng Ruan; Ningzheng Dong
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

8.  [The function and clinical value of Von Willebrand factor propeptide].

Authors:  Jie Yin; Changgeng Ruan
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2015-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.